The most common form of DM, type 2 , is projected to affect an estimated 366 million people worldwide by 2030.
The lifetime incidence of neuropathy (DPN) is approximately 45% for patients with type 2 DM and 54% to 59% for patients with type 1 DM.
Studies of nerve conduction tests performed at the time of DM diagnosis demonstrate that neuropathy is already present in patients when the neuropathy is still subclinical.